XML 67 R56.htm IDEA: XBRL DOCUMENT v3.25.3
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 05, 2025
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2021
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Interest income           $ 100,698 $ 101,236 $ 297,811 $ 309,031      
Outstanding principal balance           $ 5,370,369   $ 5,370,369   $ 4,108,913 $ 4,606,227  
Common stock share issued           31,955,538   31,955,538   23,689,135    
Other expenses $ 500                      
Accounts receivable balance           $ 18,029,485   $ 18,029,485   $ 13,478,263    
Prepaid expenses and other current assets - related party           1,657,936   1,657,936   1,310,388    
Revenue           17,110,425 12,411,048 45,568,655 40,202,238      
Loans receivable - related party current portion           714,935   714,935   614,473    
Loans receivable - related party noncurrent portion           2,897,956   2,897,956   2,876,523    
Grigorios Siokas [Member]                        
Outstanding principal balance           0   0   6,194    
Foreign curreny translation               829        
Cana Holdings Laboratories Holding Limited [Member]                        
Secured promissory note       $ 4,457,520                
Description related to interest on principal       Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.47% as of December 31, 2023). The maturity date (“Maturity Date”) of this Note shall be five (5) years from the Issue Date                
DOC Pharma S.A. [Member]                        
Interest income           50,800   $ 152,401        
Interest rate               5.50%        
Prepayment relates to purchases of inventory               $ 3,100,000        
Loan term               10 years        
Maturity date               Dec. 31, 2032        
Accounts payable and accrued expenses - related party           419,314   $ 419,314   249,768    
Prepaid balance           4,279,200   4,279,200        
Accounts receivable - related party           2,819,563   2,819,563   2,295,706    
Other expenses                       $ 7,599,545
Cumulative allowance for doubtful accounts               1,600,000        
Prepaid expenses and other current assets - related party           3,993,654   $ 3,993,654   3,284,052    
Pieces per product               1,000 pieces        
Purchased of additional licenses                   734,921 525,461  
Impairment charge                   160,947    
Revenue           694,826 61,140 $ 958,582 581,862      
Current portion of royalty agreement           500,000   500,000        
Non-current portion of royalty agreement           2,053,625   2,053,625        
Inventroy purchase           394,817 85,055 1,052,836 510,711      
Purchase of branded pharmaceuticals   $ 3,539,840 $ 1,965,600                  
Description of research and development         The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022              
Loans receivable - related party current portion           1,119,842   1,119,842   517,550    
Loans receivable - related party noncurrent portion           2,933,750   2,933,750   2,898,280    
Monthly basis instalments               37,150        
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                        
Inventroy purchase           180,189 37,338 633,462 175,123      
Dimitrios Goulielmos [Member]                        
Outstanding principal balance           11,970   11,970   10,558    
Foreign curreny translation               1,412        
Panagiotis Kozaris [Member]                        
Shares owned                     $ 51,159 $ 143,056
Prepaid expenses           194,215   194,215   194,215    
Maria Kozari [Member]                        
Accounts receivable balance           1,283,131   1,283,131   1,183,429    
Cumulative allowance for doubtful accounts               907,175   $ 735,000    
Net sales           113,430 330,995 113,521 310,128      
George Terzis [Member]                        
Unpaid salaries and bonuses           397,406   397,406        
Unpaid salaries and bonuses dues           190,000   190,000        
Kanarogloy & Sia Epe [Member]                        
Accounts payable and accrued expenses - related party           192,022   192,022        
Basotho Investment Limited [Member]                        
General and administrative expenses           $ 0 $ 0 $ 30,900 $ 61,800      
Common stock share issued           120,000   120,000